Risk of cardiovascular disease following gonadotropin‐releasing hormone agonists vs antagonists in prostate cancer: Real‐world evidence from five databases

Observational studies in prostate cancer (PCa) have shown an increased risk of cardiovascular disease (CVD) following gonadotropin‐releasing hormone (GnRH) agonists, whereas randomised‐controlled trials have shown no associations. Compared to GnRH agonists, GnRH antagonists have shown less atheroscl...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Gincy, Garmo, Hans, Scailteux, Lucie‐Marie, Balusson, Frédéric, De Coster, Greet, De Schutter, Harlinde, Kuiper, Josephina G., Oger, Emmanuel, Verbeeck, Julie, Van Hemelrijck, Mieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Cancer Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049028/
https://www.ncbi.nlm.nih.gov/pubmed/33186481
http://dx.doi.org/10.1002/ijc.33397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049028/
https://www.ncbi.nlm.nih.gov/pubmed/33186481
http://dx.doi.org/10.1002/ijc.33397

Ejemplares similares